Literature DB >> 16286623

Late development of vitelliform lesions and flecks in a patient with best disease: clinicopathologic correlation.

Robert F Mullins1, Kean T Oh, Edward Heffron, Gregory S Hageman, Edwin M Stone.   

Abstract

OBJECTIVE: To provide the clinicopathologic findings of a patient who developed the clinical characteristics of Best disease (typically considered a juvenile macular degeneration) at the age of 75 years after being documented to be ophthalmoscopically normal at the age of 51 years.
DESIGN: A member of a large family with Best disease, possessing a Y227N mutation in the VMD2 gene (the gene responsible for the disease, which encodes the bestrophin protein), developed small vitelliform lesions in both eyes at the age of 75 years and later developed yellow flecklike depositions at the level of the retinal pigment epithelium (RPE), which were also identified in fundus photographs of family members. The patient died at the age of 93 years, and the histological features of the macular lesion and peripheral flecks were examined.
RESULTS: Histopathologically, the retinal outer nuclear layer was attenuated, particularly in the macula. This attenuation was frequently associated with normal RPE. A large area of photoreceptor degeneration was present in the central macula, with loss of the underlying RPE cells. Outside of this region, the RPE density was within normal limits. The peripheral flecks were clusters of basal laminar deposits and drusen. Bestrophin immunohistochemistry revealed labeling along both the basolateral and apical membranes of the RPE.
CONCLUSIONS: Findings characteristic of Best disease may not manifest in a molecularly affected individual until late in life. Mutations in bestrophin appear to lead to extracellular deposit formation outside the macula in some families. The distribution of bestrophin in the RPE suggests that the protein may be mistargeted in those with Best disease who have the Y227N mutation, and that this may be a cause of the associated RPE and photoreceptor dysfunction.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16286623     DOI: 10.1001/archopht.123.11.1588

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  37 in total

1.  Multimodal fundus imaging in Best vitelliform macular dystrophy.

Authors:  Daniela C Ferrara; Rogério A Costa; Stephen Tsang; Daniela Calucci; Rodrigo Jorge; K Bailey Freund
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-04-23       Impact factor: 3.117

2.  Functional assessment of the fundus autofluorescence pattern in Best vitelliform macular dystrophy.

Authors:  Maurizio Battaglia Parodi; Pierluigi Iacono; Claudia Del Turco; Giacinto Triolo; Francesco Bandello
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-10-21       Impact factor: 3.117

3.  Molecular consequences of BEST1 gene mutations in canine multifocal retinopathy predict functional implications for human bestrophinopathies.

Authors:  Karina E Guziewicz; Julianna Slavik; Sarah J P Lindauer; Gustavo D Aguirre; Barbara Zangerl
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-06-23       Impact factor: 4.799

Review 4.  Bestrophin 1 and retinal disease.

Authors:  Adiv A Johnson; Karina E Guziewicz; C Justin Lee; Ravi C Kalathur; Jose S Pulido; Lihua Y Marmorstein; Alan D Marmorstein
Journal:  Prog Retin Eye Res       Date:  2017-01-30       Impact factor: 21.198

5.  Role of bestrophin-1 in store-operated calcium entry in retinal pigment epithelium.

Authors:  Néstor Más Gómez; Ernst R Tamm; Olaf Strauβ
Journal:  Pflugers Arch       Date:  2012-12-04       Impact factor: 3.657

6.  Suppression of Ca2+ signaling in a mouse model of Best disease.

Authors:  Youwen Zhang; J Brett Stanton; Jiang Wu; Kuai Yu; H Criss Hartzell; Neal S Peachey; Lihua Y Marmorstein; Alan D Marmorstein
Journal:  Hum Mol Genet       Date:  2010-01-06       Impact factor: 6.150

7.  BESTROPHIN1 mutations cause defective chloride conductance in patient stem cell-derived RPE.

Authors:  Yasmin Moshfegh; Gabriel Velez; Yao Li; Alexander G Bassuk; Vinit B Mahajan; Stephen H Tsang
Journal:  Hum Mol Genet       Date:  2016-05-18       Impact factor: 6.150

8.  Detailed analysis of retinal function and morphology in a patient with autosomal recessive bestrophinopathy (ARB).

Authors:  Christina Gerth; Robert J Zawadzki; John S Werner; Elise Héon
Journal:  Doc Ophthalmol       Date:  2008-11-05       Impact factor: 2.379

9.  New VMD2 gene mutations identified in patients affected by Best vitelliform macular dystrophy.

Authors:  D Marchant; K Yu; K Bigot; O Roche; A Germain; D Bonneau; V Drouin-Garraud; D F Schorderet; F Munier; D Schmidt; P Le Neindre; C Marsac; M Menasche; J L Dufier; R Fischmeister; C Hartzell; M Abitbol
Journal:  J Med Genet       Date:  2007-02-07       Impact factor: 6.318

10.  Functional and clinical data of Best vitelliform macular dystrophy patients with mutations in the BEST1 gene.

Authors:  Giuseppe Querques; Jennyfer Zerbib; Rossana Santacroce; Maurizio Margaglione; Nathalie Delphin; Jean-Michel Rozet; Josseline Kaplan; Domenico Martinelli; Nicola Delle Noci; Gisèle Soubrane; Eric H Souied
Journal:  Mol Vis       Date:  2009-12-31       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.